John Hancock Disciplined Value Select ETF (JDVL)
Live price chart, market sentiment, and community perspectives for John Hancock Disciplined Value Select ETF (AMEX: JDVL).
Live price chart, market sentiment, and community perspectives for John Hancock Disciplined Value Select ETF (AMEX: JDVL).
On our desk, we are looking closely at JDVL's trading frictions. While the fundamental methodology from Boston Partners targeting high-quality cyclicals makes sense on paper, a bid-ask spread hovering around 48.67 bps combined with a 0.56% expense ratio introduces a real drag for short-term positioning. Passive alternatives simply don't carry this level of implementation cost.
From a risk management standpoint, JDVL presents an interesting paradox. Its 1-year beta sits right at 0.98, and its Sharpe ratio of 1.10 looks solid in isolation. However, Morningstar's Low risk-vs-category and return-vs-category ratings show that the fund hugs the lower edge of the Large Value space, taking less risk but failing to reward investors with outsized returns.
Institutional interest in JDVL is undeniably robust for a relatively new product. With Q2 2026 regulatory filings indicating $852M invested across select large funds, and more first-time investments than exits, the smart money is establishing footprints, though liquidity and daily volume averaging around 87.5k require careful execution for larger block trades.
When evaluating the portfolio construction strategy for JDVL, the emphasis on avoiding value traps—specifically buying good companies at peak earnings—is a compelling qualitative framework. David T. Cohen's bottom-up approach focusing on valuation, fundamental quality, and business momentum provides a clear structural thesis for patient, buy-and-hold allocators.
As a quant analyst reviewing the fund's inception data from August 2025, the lack of a multi-year track record makes statistical modeling difficult. Short-term returns of +2.11% YTD and +5.33% over six months are respectable, but we lack the historical depth across various market cycles to validate true factor persistence.
Explore plasma cleansing, somatic organ swaps, and BCI.